Chiang, Shannon
Garcia Netto, Keilah
Kokkinos, John
Haghighi, Koroush S.
Raina, Aparna S.
Youkhana, Janet
Pitiyarachchi, Omali
Truong, Quach
Wenholz, Daniel
Wilkinson, John
Laczka, Olivier
Li, Xiang
Aldilla, Vina R.
Kumar, Naresh
Goldstein, David
Sharbeen, George
Phillips, Phoebe A.
Funding for this research was provided by:
Pankind Accelerator Grants
Cancer Institute NSW Translational Program Grant (2020/TPG2100)
Cancer Institute NSW Translational Program Grant (2020/TPG2100)
NHMRC Ideas Grant (APP2002707)
NHMRC Ideas Grant (APP2002707)
SPHERE/Cancer Institute NSW Translational Cancer Research Capacity Building Grant (2021/CBG0003)
Article History
Received: 1 April 2025
Accepted: 27 June 2025
First Online: 8 July 2025
Declarations
:
: As part of an industry partnership research contract with UNSW, Noxopharm provided the novel compounds to the Pancreatic Cancer Translational Research Group at UNSW led by P.A. Phillips. The therapeutic assessment of these compounds was conducted independently by the group, and the results were reported to Noxopharm as stipulated in the contract. In addition, Quach Truong, Daniel Wenholz, John Wilkinson, Olivier Laczka, and Xiang Li are paid employes of Noxopharm. All other authors have no competing interests to declare.
: The study is reported in accordance with ARRIVE guidelines.
: N. Kumar (patents: US20080306140, US20040152761)) synthesized the series of novel chromans, CRO-05, CRO-67, and CRO-68, in collaboration with Noxopharm Limited, and report a composition of matter patent for WO2023235929. As part of an industry partnership research contract with UNSW, Noxopharm provided the novel compounds to the Pancreatic Cancer Translational Research Group at UNSW led by P.A. Phillips. The therapeutic assessment of these compounds was conducted independently by the group, and the results were reported to Noxopharm as stipulated in the contract. No disclosures were reported by the other authors.